form10-q.htm
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
|
R
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the quarterly period ended March 31, 2014
OR
|
£
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from to
Commission file number 0-15327
CytRx Corporation
(Exact name of Registrant as specified in its charter)
|
Delaware
|
58-1642740
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
11726 San Vicente Blvd., Suite 650
Los Angeles, CA
|
90049
|
|
(Address of principal executive offices)
|
(Zip Code)
|
(310) 826-5648
(Registrant’s telephone number, including area code)
Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes R No £
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes R No £
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
|
Large accelerated filer £
|
Accelerated filer R
|
Non-accelerated filer £
|
Smaller reporting company £
|
| |
(Do not check if a smaller reporting company)
|
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12(b)-2 of the Exchange Act). Yes £ No R
Number of shares of CytRx Corporation common stock, $.001 par value, outstanding as of April 30, 2014: 55,776,523 shares, exclusive of treasury shares.
CYTRX CORPORATION
FORM 10-Q
TABLE OF CONTENTS
|
|
Page
|
|
PART I. — FINANCIAL INFORMATION
|
|
|
Item 1. Financial Statements (unaudited)
|
1 |
|
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
11 |
|
Item 3. Quantitative and Qualitative Disclosures About Market Risk
|
16 |
|
Item 4. Controls and Procedures
|
16 |
| |
|
|
PART II. — OTHER INFORMATION
|
|
|
Item 1A. Risk Factors
|
17 |
|
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
|
17 |
|
Item 6. Exhibits
|
17 |
| |
|
|
SIGNATURES
|
18 |
| |
|
|
INDEX TO EXHIBITS
|
19 |
PART I — FINANCIAL INFORMATION
Item 1. — Financial Statements
CYTRX CORPORATION
CONDENSED BALANCE SHEETS
(Unaudited)
|
|
|
March 31,
2014
|
|
|
December 31, 2013
|
|
|
ASSETS
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$ |
62,028,328 |
|
|
$ |
11,483,112 |
|
|
Short-term investments
|
|
|
50,584,980 |
|
|
|
27,084,980 |
|
|
Receivables
|
|
|
31,767 |
|
|
|
117,527 |
|
|
Interest receivable
|
|
|
27,775 |
|
|
|
8,464 |
|
|
Prepaid expenses and other current assets
|
|
|
1,725,893 |
|
|
|
2,329,742 |
|
|
Total current assets
|
|
|
114,398,743 |
|
|
|
41,023,825 |
|
|
Equipment and furnishings, net
|
|
|
156,958 |
|
|
|
175,452 |
|
|
Goodwill
|
|
|
183,780 |
|
|
|
183,780 |
|
|
Other assets
|
|
|
99,008 |
|
|
|
116,998 |
|
|
Total assets
|
|
$ |
114,838,489 |
|
|
$ |
41,500,055 |
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
Current liabilities:
Accounts payable
|
|
$ |
4,271,182 |
|
|
$ |
3,853,531 |
|
|
Accrued expenses and other current liabilities
|
|
|
3,047,388 |
|
|
|
2,802,833 |
|
|
Warrant liabilities
|
|
|
9,479,420 |
|
|
|
24,182,324 |
|
|
Total current liabilities
|
|
|
16,797,990 |
|
|
|
30,838,688 |
|
| |
|
|
|
|
|
|
|
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
Stockholders’ equity:
|
|
|
|
|
|
|
|
|
|
Preferred Stock, $0.01 par value, 5,000,000 shares authorized, including 25,000 shares of Series A Junior Participating Preferred Stock; no shares issued and outstanding
|
|
|
— |
|
|
|
— |
|
|
Common stock, $0.001 par value, 250,000,000 shares authorized; 55,920,319 shares issued and outstanding at March 31, 2014; 42,116,964 shares issued and outstanding at December 31, 2013
|
|
|
55,922 |
|
|
|
42,118 |
|
|
Additional paid-in capital
|
|
|
372,126,910 |
|
|
|
289,426,100 |
|
|
Treasury stock, at cost (143,796 shares at March 31, 2014 and December 31, 2013)
|
|
|
(2,417,247 |
) |
|
|
(2,417,247 |
) |
|
Accumulated deficit
|
|
|
(271,725,086 |
) |
|
|
(276,389,604 |
) |
|
Total stockholders’ equity
|
|
|
98,040,499 |
|
|
|
10,661,367 |
|
|
Total liabilities and stockholders’ equity
|
|
$ |
114,838,489 |
|
|
$ |
41,500,055 |
|
The accompanying notes are an integral part of these condensed financial statements.
CYTRX CORPORATION
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)
| |
|
Three Months Ended
March 31,
|
|
| |
|
2014
|
|
|
2013
|
|
|
Revenue:
|
|
|
|
|
|
|
|
License revenue
|
|
$ |
— |
|
|
$ |
— |
|
| |
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
|
6,987,848 |
|
|
|
3,188,759 |
|
|
General and administrative
|
|
|
3,131,074 |
|
|
|
1,817,325 |
|
| |
|
|
10,118,922 |
|
|
|
5,006,084 |
|
| |
|
|
|
|
|
|
|
|
|
Loss before other income (loss)
|
|
|
(10,118,922 |
) |
|
|
(5,006,084 |
) |
| |
|
|
|
|
|
|
|
|
|
Other income (loss):
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
70,638 |
|
|
|
40,258 |
|
|
Other income, net
|
|
|
9,898 |
|
|
|
196,937 |
|
|
Gain (loss) on warrant derivative liabilities
|
|
|
14,702,904 |
|
|
|
(2,095,220 |
) |
| |
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$ |
4,664,518 |
|
|
$ |
(6,864,109 |
) |
| |
|
|
|
|
|
|
|
|
|
Basic net income (loss) per share
|
|
$ |
0.09 |
|
|
$ |
(0.23 |
) |
| |
|
|
|
|
|
|
|
|
|
Basic weighted-average shares outstanding
|
|
|
50,314,719 |
|
|
|
30,417,370 |
|
| |
|
|
|
|
|
|
|
|
|
Diluted net income (loss) per share
|
|
$ |
0.08 |
|
|
$ |
(0.23 |
) |
| |
|
|
|
|
|
|
|
|
|
Diluted weighted-average shares outstanding
|
|
|
55,727,056 |
|
|
|
30,417,370 |
|
| |
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these condensed financial statements
CYTRX CORPORATION
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)
| |
|
Three Months Ended March 31,
|
|
|
|
|
2014
|
|
|
2013
|
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$ |
4,664,518 |
|
|
$ |
(6,864,109 |
) |
|
Adjustments to reconcile net income (loss) to net cash used in operating activities:
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
32,659 |
|
|
|
29,539 |
|
|
Stock compensation and warrant expense
|
|
|
1,750,222 |
|
|
|
308,008 |
|
|
Fair value adjustment on warrant liabilities
|
|
|
(14,702,904 |
) |
|
|
2,095,220 |
|
|
Net foreign exchange (gain) loss
|
|
|
177 |
|
|
|
(132,244 |
) |
|
Income from receipt of Mast Therapeutics, Inc. shares
|
|
|
— |
|
|
|
(62,945 |
) |
|
Changes in assets and liabilities:
|
|
|
|
|
|
|
|
|
|
Receivables
|
|
|
85,760 |
|
|
|
99,508 |
|
|
Interest receivable
|
|
|
(19,311 |
) |
|
|
(13,651 |
) |
|
Prepaid expenses and other current assets
|
|
|
621,839 |
|
|
|
(250,057 |
) |
|
Accounts payable
|
|
|
410,109 |
|
|
|
(1,210,009 |
) |
|
Accrued expenses and other current liabilities
|
|
|
244,378 |
|
|
|
88,767 |
|
|
Net cash used in operating activities
|
|
|
(6,912,553 |
) |
|
|
(5,911,973 |
) |
| |
|
|
|
|
|
|
|
|
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
|
(Purchase of)/ Proceeds from sale of short-term investments
|
|
|
(23,500,000 |
) |
|
|
3,000,000 |
|
|
Purchases of equipment and furnishings
|
|
|
(6,623 |
) |
|
|
(2,444 |
) |
|
Net cash provided by (used in) investing activities
|
|
|
(23,506,623 |
) |
|
|
2,997,556 |
|
| |
|
|
|
|
|
|
|
|
|
Cash flows from financing activities:
Net proceeds from public offering
|
|
|
80,535,401 |
|
|
|
— |
|
|
Proceeds from issuance of restricted stock to employee
|
|
|
100 |
|
|
|
— |
|
|
Net proceeds from exercise of warrants
|
|
|
428,891 |
|
|
|
— |
|
|
Net cash provided by financing activities
|
|
|
80,964,392 |
|
|
|
— |
|
| |
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
50,545,216 |
|
|
|
(2,914,417 |
) |
|
Cash and cash equivalents at beginning of period
|
|
|
11,483,112 |
|
|
|
14,344,088 |
|
|
Cash and cash equivalents at end of period
|
|
$ |
62,028,328 |
|
|
$ |
11,429,671 |
|
| |
|
|
|
|
|
|
|
|
|
Supplemental disclosure of cash flow information:
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
Equipment and furnishings purchased on credit
|
|
$ |
7,542 |
|
|
$ |
793 |
|
| |
|
|
|
|
|
|
|
|
|
Cashless warrant exercises
|
|
$ |
133 |
|
|
|
— |
|
| |
|
|
|
|
|
|
|
|
|
Cash paid for income taxes
|
|
$ |
3,151 |
|
|
$ |
1,600 |
|
| |
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these condensed financial statements.
NOTES TO CONDENSED FINANCIAL STATEMENTS
March 31, 2014
(Unaudited)
1. Description of Company and Basis of Presentation
CytRx Corporation (“CytRx” or the “Company”) is a biopharmaceutical research and development company specializing in oncology. The Company currently is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its modified version of the widely-used chemotherapeutic agent, doxorubicin. CytRx has reported positive top-line results from its global Phase 2b clinical trial with aldoxorubicin as a treatment for soft tissue sarcoma, has completed a Phase 1b/2 clinical trial primarily in the same indication, a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors, and a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors. CytRx also has initiated under a Special Protocol Assessment, or “SPA,” granted by the U.S. Food and Drug Administration, or the “FDA,” a pivotal Phase 3 global trial of aldoxorubicin as a therapy for patients with soft tissue sarcoma whose tumors have progressed following treatment with chemotherapy. The Company has initiated Phase 2 clinical trials with aldoxorubicin in patients with late-stage glioblastoma (brain cancer) and AIDS-related Kaposi’s sarcoma. CytRx is opening a research and development laboratory in Freiberg, Germany to expand its pipeline of oncology candidates based on a linker platform technology that can be utilized with multiple chemotherapeutic agents and may allow for greater concentration of drug at tumor sites. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib. CytRx has completed its evaluation of bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (“B-CLL”), and plans to seek a partner for further development of bafetinib. The Company ceased its Phase 2b clinical trial of tamibarotene in patients with non-small-cell lung cancer after it failed to show efficacy.
The accompanying condensed financial statements at March 31, 2014 and for the three-month periods ended March 31, 2014 and 2013, respectively, are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Prior period figures have been reclassified, wherever necessary, to conform to current presentation. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December 31, 2013 have been derived from the Company’s audited financial statements as of that date.
The financial statements included herein have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The financial statements should be read in conjunction with the Company’s audited financial statements contained in its Annual Report on Form 10-K for the year ended December 31, 2013. The Company’s operating results will fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods.
2. Recent Accounting Pronouncements
We have reviewed all of the recent accounting pronouncements and have determined that they have not or will not have a material impact on our financial statements, or simply do not apply to our operations.
3. Short-term Investments
The Company held $50.6 million of short-term investments at March 31, 2014, as compared to $27.1 million at December 31, 2013. The Company has classified these investments as available for sale. These investments are federally insured certificates of deposit and are detailed as follows: $10.0 million with a maturity date of April 24, 2014; $12.1 million with a maturity date of May 1, 2014; $11.5 million with a maturity date of August 28, 2014; $5.0 million with a maturity date of October 30, 2014; and $12.0 million with a maturity date of February 26, 2015.
4. Investment in Mast Therapeutics, Inc.
On April 8, 2011, Mast Therapeutics, Inc. (formerly ADVENTRX Pharmaceuticals) completed its acquisition of SynthRx, Inc., in which the Company held a 19.1% interest. As a result of the transaction, the Company received approximately 126,000 shares of common stock of Mast Therapeutics, which it sold on October 11, 2011 for $112,200. In June 2012, the Company received an additional 38,196 shares of common stock of Mast Therapeutics that had been held in an escrow established in connection with the acquisition, which it sold on June 6, 2012 for $17,900. The Company received an additional 92,566 shares in January 2013 and an additional 47,745 shares in June 2013, all of which shares were sold in June 2013 for $60,566. If all of the development milestones under the acquisition agreement were to be achieved, the Company would be entitled to receive up to 2.8 million additional Mast Therapeutics shares. Our former interest in SynthRx had a zero carrying value.
5. Basic and Diluted Net Income (Loss) Per Common Share
Basic and diluted net income (loss) per common share is computed based on the weighted-average number of common shares outstanding. Common share equivalents (which consist of options, warrants and restricted stock) are excluded from the computation of diluted net income (loss) per common share where the effect would be anti-dilutive. Common share equivalents that could potentially dilute net income (loss) per share in the future, and which were excluded from the computation of diluted income (loss) per share, totaled 9.2 million shares for the three-month period ended March 31, 2014, and 11.0 million for the three-month period ended March 31, 2013.
6. Warrant Liabilities
Liabilities measured at market value on a recurring basis include warrant liabilities resulting from the Company’s past equity financings. In accordance with ASC 815-40, Derivatives and Hedging – Contracts in Entity’s Own Equity (“ASC 815-40”), the warrant liabilities are being marked to market until they are completely settled. The warrants are valued using the Black-Scholes method, using assumptions consistent with our application of ASC 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”). The gain or loss resulting from the marked to market calculation is shown on the Condensed Statements of Operations as gain (loss) on warrant derivative liabilities. The Company recognized a gain of $14.7 million and a loss of $2.1 million for the three-month periods ended March 31, 2014 and 2013, respectively. The following reflects the weighted-average assumptions for each of the three-month periods indicated:
| |
|
Three Months Ended March 31,
|
|
|
|
|
2014
|
|
|
2013
|
|
| |
|
|
|
|
|
|
|
Risk-free interest rate
|
|
|
0.63 |
% |
|
|
0.45 |
% |
|
Expected dividend yield
|
|
|
0 |
% |
|
|
0 |
% |
|
Expected lives
|
|
|
2.21 |
|
|
|
3.21 |
|
|
Expected volatility
|
|
|
85.7 |
% |
|
|
69.0 |
% |
|
Warrants classified as liabilities (in shares)
|
|
|
6,984,716 |
|
|
|
6,984,716 |
|
|
Gain (loss) on warrant liabilities
|
|
$ |
14,702,904 |
|
|
$ |
(2,095,220 |
) |
The dividend yield assumption of zero is based upon the fact that the Company has never paid and presently has no intention of paying cash dividends. The risk-free interest rate used for each warrant classified as a derivative is equal to the U.S. Treasury rates in effect at March 31 of each year presented. The expected lives are based on the remaining contractual lives of the related warrants at the valuation date.
7. Stock Based Compensation
The Company has a 2000 Long-Term Incentive Plan. As of March 31, 2014, there were approximately 0.8 million shares subject to outstanding stock options under this plan, which expired on August 6, 2010. Thus, no further shares are available for future grant under this plan.
The Company also has a 2008 Stock Incentive Plan. As of March 31, 2014, there were 5.9 million shares subject to outstanding stock options and 4.1 million shares available for future grant under this plan.
The Company follows ASC 718, Compensation-Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees.
For stock options and stock warrants paid in consideration of services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of ASC 505-50.
Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period, the value of these options, as calculated using the Black-Scholes option-pricing model, is determined, and compensation expense recognized or recovered during the period is adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense is subject to adjustment until the common stock options are fully vested.
The following table sets forth the total stock-based compensation expense resulting from stock options and warrants included in the Company’s unaudited interim statements of operations:
| |
|
Three Months Ended March 31,
|
|
| |
|
2014
|
|
|
2013
|
|
|
Research and development — employee
|
|
$ |
175,153 |
|
|
$ |
50,172 |
|
|
General and administrative — employee
|
|
|
311,960 |
|
|
|
184,640 |
|
|
Total employee stock-based compensation
|
|
$ |
487,113 |
|
|
$ |
234,812 |
|
| |
|
|
|
|
|
|
|
|
|
Research and development — non-employee
|
|
$ |
86,539 |
|
|
$ |
— |
|
|
General and administrative — non-employee
|
|
|
191,992 |
|
|
|
27,212 |
|
|
Total non-employee stock-based compensation
|
|
$ |
278,531 |
|
|
$ |
27,212 |
|
During the three-month period ended March 31, 2014, the Company issued stock options to purchase 270,000 shares of its common stock and issued warrants to purchase 25,000 shares of its stock with an exercise of $5.60. The fair value of the stock options and warrants granted in the current three-month period was estimated using the Black-Scholes option-pricing model, based on the following assumptions:
| |
|
Three Months Ended
March 31, 2014
|
|
|
Three Months Ended
March 31, 2013
|
|
|
Risk-free interest rate
|
|
|
1.98 |
% |
|
|
1.16 |
% |
|
Expected volatility
|
|
|
87.8% - 89.6 |
% |
|
|
85.4% - 85.8 |
% |
|
Expected lives (years)
|
|
|
6 - 10 |
|
|
|
6 |
|
|
Expected dividend yield
|
|
|
0.00 |
% |
|
|
0.00 |
% |
The Company’s computation of expected volatility is based on the historical daily volatility of its publicly traded stock. For option grants issued during the three-month period ended March 31, 2014, the Company used a calculated volatility for each grant. The Company uses historical information to compute expected lives. In the three-month period ended March 31, 2014, the contractual term of the options granted was ten years and the Company used six years as the expected life. The contractual term for the warrants issued was ten years. The dividend yield assumption of zero is based upon the fact the Company has never paid and presently has no intention of paying cash dividends. The risk-free interest rate used for each grant is equal to the U.S. Treasury rates in effect at the time of the grant for instruments with a similar expected life. Based on historical experience, for the three-month period ended March 31, 2014, the Company has estimated an annualized forfeiture rate of 12% for options granted to its employees, 2% for options granted to senior management and 0% for options granted to directors and non-employees. For the comparative three-month period ended March 31, 2013, the Company has estimated an annualized forfeiture rate of 13% for options granted to its employees and 3% for options granted to senior executives. Compensation costs will be adjusted for future changes in estimated forfeitures. The Company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated. No amounts relating to employee stock-based compensation have been capitalized.
As of March 31, 2014, there remained approximately $4.6 million of unrecognized compensation expense related to unvested stock options granted to current and former employees, directors and consultants, to be recognized as expense over a weighted-average period of 1.24 years. Presented below is the Company’s stock option activity:
|
|
|
Three Months Ended March 31, 2014
|
|
|
|
|
Number of Options (Employees)
|
|
|
Number of Options (Non-Employees)
|
|
|
Total Number of Options
|
|
|
Weighted-Average Exercise Price
|
|
|
Outstanding at January 1, 2014
|
|
|
6,228,593 |
|
|
|
167,143 |
|
|
|
6,395,736 |
|
|
$ |
3.11 |
|
|
Granted
|
|
|
270,000 |
|
|
|
|
|
|
|
270,000 |
|
|
$ |
5.38 |
|
|
Outstanding at March 31, 2014
|
|
|
6,498,593 |
|
|
|
167,143 |
|
|
|
6,665,736 |
|
|
$ |
3.20 |
|
|
Options exercisable at March 31, 2014
|
|
|
3,406,261 |
|
|
|
167,143 |
|
|
|
3,573,404 |
|
|
$ |
3.74 |
|
A summary of the unvested stock options as of March 31, 2014, and changes during the three-month period then ended, are presented below:
| |
|
Number of Options (Employees)
|
|
|
Number of Options (Non-Employees)
|
|
|
Total Number of Options
|
|
|
Weighted-Average Grant Date Fair Value per Share
|
|
|
Non-vested at January 1, 2014
|
|
|
3,102,873 |
|
|
|
— |
|
|
|
3,102,873 |
|
|
$ |
1.66 |
|
|
Granted
|
|
|
270,000 |
|
|
|
— |
|
|
|
270,000 |
|
|
$ |
3.97 |
|
|
Vested
|
|
|
(280,541 |
) |
|
|
— |
|
|
|
(280,541 |
) |
|
$ |
1.68 |
|
|
Non-vested at March 31, 2014
|
|
|
3,092,332 |
|
|
|
— |
|
|
|
3,092,332 |
|
|
$ |
1.86 |
|
The following table summarizes significant ranges of outstanding stock options under the Company’s plans at March 31, 2014:
|
Range of Exercise Prices
|
|
Number of Options
|
|
|
Weighted-Average Remaining Contractual Life (years)
|
|
|
Weighted-Average Exercise Price
|
|
|
Number of Options Exercisable
|
|
|
Weighted-Average Remaining Contractual Life (years)
|
|
|
Weighted-Average Exercise Price
|
|
|
$1.83 - $2.50
|
|
|
5,130,056 |
|
|
|
9.21 |
|
|
$ |
2.21 |
|
|
|
2,374,550 |
|
|
|
9.21 |
|
|
$ |
2.15 |
|
|
$2.51 – $3.50
|
|
|
194,482 |
|
|
|
6.69 |
|
|
$ |
2.79 |
|
|
|
153,291 |
|
|
|
6.69 |
|
|
$ |
2.69 |
|
|
$3.51 – $8.00
|
|
|
962,701 |
|
|
|
6.69 |
|
|
$ |
6.31 |
|
|
|
667,066 |
|
|
|
6.69 |
|
|
$ |
6.75 |
|
|
$8.01 – $32.55
|
|
|
378,497 |
|
|
|
2.88 |
|
|
$ |
8.86 |
|
|
|
378,497 |
|
|
|
2.88 |
|
|
$ |
8.86 |
|
| |
|
|
6,665,736 |
|
|
|
8.41 |
|
|
$ |
3.20 |
|
|
|
3,573,404 |
|
|
|
8.41 |
|
|
$ |
3.74 |
|
The aggregate intrinsic value of outstanding options as of March 31, 2014 was $11.88 million, which represents options whose exercise price was less than the closing fair market value of the Company’s common stock on March 31, 2014 of $3.49.
There were 7,894,791 and 8,324,609 warrants outstanding at March 31, 2014 and December 31, 2013, respectively.
Restricted Stock
On January 1, 2014, the Company granted to Dr. Daniel Levitt, Executive Vice President and Chief Medical Officer, 100,000 shares of CytRx Corporation restricted stock pursuant to the 2008 Plan, of which 50,000 shares will vest on June 30, 2014, and the remaining 50,000 shares will vest over the subsequent six months, provided that Dr. Levitt remains employed by the Company on each such date. The Company also granted to Dr. Levitt 100,000 shares of CytRx Corporation restricted stock pursuant to the 2008 Plan on December 31, 2012, which shares have now fully vested. The fair value of the restricted stock is based on the market price of the Company’s shares on the grant date less the par value received as consideration. The fair value of the restricted shares granted on January 1, 2014 was $627,000, and the fair value of the restricted shares granted on December 31, 2012 was $186,900. The stock-based compensation expense relating to restricted stock included in the company’s unaudited statements of operations for the three-months ended March 31, 2014 and 2013, respectively was $154,578 and $45,984.
8. Fair Value Measurements
Assets and liabilities recorded at fair value on the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs are as follows:
Level 1 – quoted prices in active markets for identical assets or liabilities.
Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.
Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.
The following table summarizes fair value measurements by level at March 31, 2014 for assets and liabilities measured at fair value on a recurring basis:
|
(In thousands)
|
|
Level I
|
|
|
Level II
|
|
|
Level III
|
|
|
Total
|
|
|
Cash equivalents
|
|
$ |
57,238 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
57,238 |
|
|
Short-term investments
|
|
|
50,585 |
|
|
|
— |
|
|
|
— |
|
|
|
50,585 |
|
|
Warrant liabilities
|
|
|
— |
|
|
|
— |
|
|
|
(9,479 |
) |
|
|
(9,479 |
) |
The following table summarizes fair value measurements by level at December 31, 2013 for assets and liabilities measured at fair value on a recurring basis:
|
(In thousands)
|
|
Level I
|
|
|
Level II
|
|
|
Level III
|
|
|
Total
|
|
|
Cash equivalents
|
|
$ |
10,281 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
10,281 |
|
|
Short-term investments
|
|
|
27,085 |
|
|
|
— |
|
|
|
— |
|
|
|
27,085 |
|
|
Warrant liabilities
|
|
|
— |
|
|
|
— |
|
|
|
(24,182 |
) |
|
|
(24,182 |
) |
Liabilities measured at market value on a recurring basis include warrant liabilities resulting from the Company’s July 2009 and August 2011 equity financings. In accordance with ASC 815-40, the warrant liabilities are marked to market each quarter-end until they are completely settled. The warrants are valued using the Black-Scholes method, using assumptions consistent with the Company’s application of ASC 505-50. The change in the fair value of the liabilities classified in Level III is due to the unrealized gain of $14.7 million recognized and the gain is presented in the Condensed Statement of Operations. See Warrant Liabilities above.
The Company considers carrying amounts of accounts receivable, accounts payable and accrued expenses to approximate fair value due to the short-term nature of these financial instruments.
The Company’s non-financial assets are measured at fair value when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized. The Company’s non-financial assets were not material at March 31, 2014 or 2013.
9. Liquidity and Capital Resources
At March 31, 2014, the Company had cash and cash equivalents of approximately $62.0 million and short-term investments of approximately $50.6 million. Management believes that the Company’s current cash on hand and short-term investments will be sufficient to fund its operations for the foreseeable future. The estimate is based, in part, upon the Company’s currently projected expenditures for the remainder of 2014 and the first three months of 2015 of approximately $43.2 million, which includes approximately $29.2 million for its clinical programs for aldoxorubicin, approximately $1.9 million for pre-clinical development of new albumin-binding cancer drugs, approximately $4.3 million for general operation of its clinical programs, and approximately $7.8 million for other general and administrative expenses. These projected expenditures are also based upon numerous other assumptions and subject to many uncertainties, and our actual expenditures may be significantly different from these projections.
If the Company obtains marketing approval and successfully commercializes aldoxorubicin or other product candidates, the Company anticipates it will take several years, and possibly longer, for it to generate significant recurring revenue. The Company will be dependent on future financing and possible strategic partnerships or asset sales until such time, if ever, as it can generate significant recurring revenue. The Company has no commitments from third parties to provide any additional financing, and it may not be able to obtain future financing on favorable terms, or at all. If the Company fails to obtain sufficient funding when needed, it may be forced to delay, scale back or eliminate all or a portion of its development programs or clinical trials, seek to license to other companies its product candidates or technologies that it would prefer to develop and commercialize itself, or seek to sell some or all of its assets or merge with or be acquired by another company.
10. Equity Transactions
On January 1, 2014, the Company granted 100,000 shares of restricted stock to Dr. Daniel Levitt, Executive Vice President and Chief Medical Officer (see Note 7).
On February 5, 2014, the Company completed an $86.0 million underwriter public offering, in which it sold and issued 13,225,000 shares of common stock at a price of $6.50 per share. Net of underwriting discounts, legal, accounting and other offering expenses, the Company received proceeds of approximately $80.5 million.
On March 15, 2014, the Company issued 200,000 common shares to KTB Tumorforschungs GmbH, or “KTB”, the licensor of aldoxorubicin, in connection with the establishment of our Freiburg, Germany research and development laboratory. The fair value of the shares was $0.8 million.
In the first quarter of 2014, we issued approximately 278,000 common shares for $0.4 million resulting from the exercise of warrants.
On October 15, 2013, the Company completed a $25.9 million underwritten public offering, in which it sold and issued 11.5 million shares of common stock at a price of $2.25 per share. Net of underwriting discounts, legal, accounting and other offering expenses, the Company received proceeds of approximately $24.1 million.
11. Income Taxes
The Company completed an analysis of changes in ownership and concluded the net operating loss carryforwards as of December 31, 2012 are not subject to limitation under Section 382 of the Internal Revenue Code.
12. Commitments and contingencies
Commitments
We have an agreement with KTB, for the license of patent rights held by KTB for the worldwide development and commercialization of aldoxorubicin. Under the agreement, we must make payments to KTB in the aggregate of $7.5 million upon meeting clinical and regulatory milestones up to and including the product’s second final marketing approval. In the first quarter of 2014, we met two clinical milestones, resulting in a requirement to pay $2.0 million to KTB, of which $1.0 million was paid in March 2014, and the remainder was included in accounts payable, and subsequently paid on April 1st, 2014. We also agreed to pay:
|
·
|
commercially reasonable royalties based on a percentage of net sales (as defined in the agreement);
|
|
·
|
a percentage of non-royalty sub-licensing income (as defined in the agreement); and
|
|
·
|
milestones of $1 million for each additional final marketing approval that we obtain.
|
In the event that we must pay a third party in order to exercise our rights to the intellectual property under the agreement, we will deduct a percentage of those payments from the royalties due KTB, up to an agreed upon cap.
Contingencies
We are occasionally involved in legal proceedings and other matters arising from the normal course of business. There are currently three purported federal shareholder class action securities litigations against the Company and an Officer, in the United States District Court for the Central District of California. These actions state substantially the same causes of action, and allegedly arise from the same events.
Chen v. CytRx Corporation, et al.
On March 14, 2014, a purported class action lawsuit was filed against the Company and an officer, DreamTeamGroup and MissionIR in the United States District Court for the Central District of California, captioned Chen vs. CytRx Corporation, et al., No. CV-14-1956-GHK-(RTWx). The complaint purports to be brought on behalf of all shareholders who purchased the Company’s common stock between November 22, 2013 and March 13, 2014. The complaint alleges that defendants violated the federal securities laws in connection with various public statements purportedly issued by us or on our behalf. The complaint seeks compensatory damages in an unspecified amount and attorney’s fees and costs.
Perri v. CytRx Corporation, et al.
On March 18, 2014, a purported class action lawsuit was filed against the Company and an officer, in the United States District Court for the Central District of California, captioned Perri v. CytRx Corporation, et al., No. 2:14-cv-02052-DDP-(JCGx). The complaint, which purports to be brought on behalf of all shareholders who purchased the Company’s common stock between November 20, 2013 and March 13, 2014, asserts claims substantially identical to those asserted in Chen v. CytRx Corporation, et al., No. CV-14-1956-GHK-(RTWx), described above. The complaint seeks compensatory damages in an unspecified amount and attorney’s fees and costs.
Kim v. CytRx Corporation, et al.
On April 9, 2014, a purported class action lawsuit was filed against the Company and an officer, in the United States District Court for the Central District of California, captioned Kim v. CytRx Corporation, et al., No. 2:14-cv-02689-DMG-(AJWx). The complaint, which purports to be brought on behalf of all shareholders who purchased the Company’s common stock between November 22, 2013 and March 13, 2014, asserts claims substantially identical to those asserted in Chen v. CytRx Corporation, et al., No. CV-14-1956-GHK-(RTWx), and Perri v. CytRx Corporation, et al., No. 2:14-cv-02052-DDP-(JCGx), described above. The complaint seeks compensatory damages in an unspecified amount and attorney’s fees and costs.
There is also a purported state shareholder class action securities litigation.
Rajasekaran v. CytRx Corporation, et al.
On April 3, 2014, a purported class action lawsuit was filed against the Company and certain officers and each director, as well as certain underwriters, in the Superior Court of California, County of Los Angeles, captioned Rajasekaran v. CytRx Corporation, et al., BC541426. The complaint purports to be brought on behalf of all shareholders who purchased or otherwise acquired the Company’s common stock pursuant and/or traceable to the Company’s secondary common stock offering, which closed on February 5, 2014. The complaint alleges that defendant violated the federal securities laws by making materially false and misleading statements in filings with the SEC. The complaint seeks compensatory damages in an unspecified amount, rescission, and attorney’s fees and costs.
We intend to vigorously defend against the foregoing complaints. Based on the very early stage of litigation, it is not possible to estimate the amount or range of possible loss, if any, that might result from an adverse judgment or a settlement of these matters.
Item 2. — Management’s Discussion and Analysis of Financial Condition and Results of Operations
Forward Looking Statements
From time to time, we make oral and written statements that may constitute “forward-looking statements” (rather than historical facts) as defined in the Private Securities Litigation Reform Act of 1995 or by the SEC in its rules, regulations and releases, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We desire to take advantage of the “safe harbor” provisions in the Private Securities Litigation Reform Act of 1995 for forward-looking statements made from time to time, including, but not limited to, the forward-looking statements made in this Quarterly Report, as well as those made in our other filings with the SEC.
All statements in this Quarterly Report, including statements in this section, other than statements of historical fact are forward-looking statements for purposes of these provisions, including statements of our current views with respect to the recent developments regarding our business strategy, business plan and research and development activities, our future financial results, and other future events. These statements include forward-looking statements both with respect to us, specifically, and the biotechnology industry, in general. In some cases, forward-looking statements can be identified by the use of terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “estimates,” “potential” or “could” or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, there can be no assurance that such expectations or any of the forward-looking statements will prove to be correct, and actual results could differ materially from those projected or assumed in the forward-looking statements.
All forward-looking statements involve inherent risks and uncertainties, and there are or will be important factors that could cause actual results to differ materially from those indicated in these statements. We believe that these factors include, but are not limited to, the factors discussed in this section and under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2013, which should be reviewed carefully. If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we anticipate. Please consider our forward-looking statements in light of those risks as you read this Quarterly Report. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.
Overview
CytRx Corporation (“CytRx,” the “Company,” “we,” “us” or “our”) is a biopharmaceutical research and development company specializing in oncology. We currently are focused on the clinical development of aldoxorubicin (formerly known as INNO-206), our modified version of the widely-used chemotherapeutic agent, doxorubicin. We have reported positive top-line results from our global Phase 2b clinical trial with aldoxorubicin as a treatment for soft tissue sarcoma, have completed a Phase 1b/2 clinical trial primarily in the same indication, a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors, and a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors. We also have initiated under a Special Protocol Assessment, or “SPA,” granted by the U.S. Food and Drug Administration, or the “FDA,” a pivotal Phase 3 global trial of aldoxorubicin as a therapy for patients with soft tissue sarcoma whose tumors have progressed following treatment with chemotherapy. We have initiated Phase 2 clinical trials with aldoxorubicin in patients with late-stage glioblastoma (brain cancer) and AIDS-related Kaposi’s sarcoma. We are opening a research and development laboratory in Freiberg, Germany to expand our pipeline of oncology candidates based on a linker platform technology that can be utilized with multiple chemotherapeutic agents and may allow for greater concentration of drug at tumor sites. We also have rights to two additional drug candidates, tamibarotene and bafetinib. We have completed our evaluation of bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (“B-CLL”), and plan to seek a partner for further development of bafetinib. We ceased our Phase 2b clinical trial of tamibarotene in patients with non-small-cell lung cancer after it failed to show efficacy.
Critical Accounting Policies and Estimates
Management’s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, impairment of long-lived assets, including finite-lived intangible assets, research and development expenses and clinical trial expenses and stock-based compensation expense.
We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.
Our significant accounting policies are summarized in Note 2 to our financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2013. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our financial statements.
Revenue Recognition
Revenue consists of license fees from strategic alliances with pharmaceutical companies, as well as service and grant revenues. Service revenue consists of contract research and laboratory consulting. Grant revenues consist of government and private grants.
Monies received for license fees are deferred and recognized ratably over the performance period in accordance with Financial Accounting Standards Board (“FASB”) Accounting Codification Standards (“ASC”) ASC 605-25, Revenue Recognition – Multiple-Element Arrangements (“ASC 605-25”). Milestone payments will be recognized upon achievement of the milestone as long as the milestone is deemed substantive and we have no other performance obligations related to the milestone and collectability is reasonably assured, which is generally upon receipt, or recognized upon termination of the agreement and all related obligations. Deferred revenue represents amounts received prior to revenue recognition.
Revenues from contract research, government grants, and consulting fees are recognized over the respective contract periods as the services are performed, provided there is persuasive evidence or an arrangement, the fee is fixed or determinable and collection of the related receivable is reasonably assured. Once all conditions of the grant are met and no contingencies remain outstanding, the revenue is recognized as grant fee revenue and an earned but unbilled revenue receivable is recorded.
Research and Development Expenses
Research and development expenses consist of direct and overhead-related research expenses and are expensed as incurred. Costs to acquire technologies, including licenses, that are utilized in research and development and that have no alternative future use are expensed when incurred. Costs of technology developed for use in our products are expensed as incurred until technological feasibility has been established.
Clinical Trial Expenses
Clinical trial expenses, which are included in research and development expenses, include obligations resulting from our contracts with various clinical research organizations in connection with conducting clinical trials for our product candidates. We recognize expenses for these activities based on a variety of factors, including actual and estimated labor hours, clinical site initiation activities, patient enrollment rates, estimates of external costs and other activity-based factors. We believe that this method best approximates the efforts expended on a clinical trial with the expenses we record. We adjust our rate of clinical expense recognition if actual results differ from our estimates. If our estimates are incorrect, clinical trial expenses recorded in future periods could vary.
Stock-Based Compensation
Our stock-based employee compensation plans are described in Note 7 of the Notes to Condensed Financial Statements included in this Quarterly Report. We follow ASC 718, Compensation-Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees.
For stock options and stock warrants paid in consideration of services rendered by non-employees, we recognize compensation expense in accordance with the requirements of ASC 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”).
Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to performance, the value of these options is determined using the Black-Scholes option-pricing model, and compensation expense recognized or recovered during the period is adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future compensation expense is subject to adjustment until the common stock options or warrants are fully vested.
The fair value of each stock option grant is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option-pricing model, based on an expected forfeiture rate that is adjusted for our actual experience. If our Black-Scholes option-pricing model assumptions or our actual or estimated forfeiture rate are different in the future, it could materially affect our compensation expense recorded in future periods.
Impairment of Long-Lived Assets
We review long-lived assets, including finite-lived intangible assets, for impairment on an annual basis as of December 31, or on an interim basis if an event occurs that might reduce the fair value of such assets below their carrying values. An impairment loss would be recognized based on the difference between the carrying value of the asset and its estimated fair value, which would be determined based on either discounted future cash flows or other appropriate fair value methods. If our estimates used in the determination of either discounted future cash flows or other appropriate fair value methods are not accurate as compared to actual future results, we may be required to record an impairment charge.
Net Income (Loss) per Share
Basic and diluted net income (loss) per common share is computed using the weighted-average number of common shares outstanding. Potentially dilutive stock options and warrants to purchase 9.2 million shares for the three-month period ended March 31, 2014, and 11.0 million shares for the three-month period ended March 31, 2013, were excluded from the computation of diluted net income (loss) per share, because the effect would be anti-dilutive.
Warrant Liabilities
Liabilities measured at market value on a recurring basis include warrant liabilities resulting from our July 2009 and August 2011 equity financings. In accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to and Potentially Settled in a Company’s Own Stock (“ASC 815-40”), the warrant liabilities are marked to market each quarter-end until they are completely settled. The warrants are valued using the Black-Scholes method, using assumptions consistent with our application of ASC 505-50. The gain or loss resulting from the marked to market calculation is shown on the statements of operations as a gain or loss on warrant derivative liabilities.
Investment in Mast Therapeutics, Inc.
On April 8, 2011, Mast Therapeutics, Inc. (formerly “ADVENTRX Pharmaceuticals”) completed its acquisition of SynthRx, Inc., in which we held a 19.1% interest. As a result of the transaction, we received approximately 126,000 shares of common stock of Mast Therapeutics, which we sold on October 11, 2011 for $112,200. In June 2012, we received an additional 38,196 shares of common stock of Mast Therapeutics that had been held in an escrow established in connection with the acquisition, which we sold on June 6, 2012 for $17,900. We received an additional 92,566 shares in January 2013 and an additional 47,745 shares in June 2013, all of which shares were sold in June 2013 for $60,566. If all of the development milestones under the acquisition agreement were to be achieved, we would be entitled to receive up to 2.8 million additional Mast Therapeutics shares. At the time of the sale, our interest in SynthRx had a zero carrying value.
Liquidity and Capital Resources
We have relied primarily upon proceeds from sales of our equity securities and the exercise of options and warrants, and to a much lesser extent upon payments from our strategic partners and licensees, to generate funds needed to finance our business and operations.
At March 31, 2014, we had cash and cash equivalents of approximately $62.0 million and short-term investments of approximately $50.6 million. Management believes that our current cash on hand and short-term investments will be sufficient to fund our operations for the foreseeable future. The estimate is based, in part, upon our currently projected expenditures for the remainder of 2014 and the first three months of 2015 of approximately $43.2 million, which includes approximately $29.2 million for our clinical programs for aldoxorubicin, approximately $1.9 million for pre-clinical development of new albumin-binding cancer drugs, approximately $4.3 million for general operation of our clinical programs, and approximately $7.8 million for other general and administrative expenses. These projected expenditures are also based upon numerous other assumptions and subject to many uncertainties, and our actual expenditures may be significantly different from these projections.
If we obtain marketing approval and successfully commercialize one or more of aldoxorubicin or our other product candidates, we anticipate it will take several years and possibly longer, for us to generate significant recurring revenue. We will be dependent on future financing and possible strategic partnerships or asset sales until such time, if ever, as we can generate significant recurring revenue. We have no commitments from third parties to provide us with any additional financing, and we may not be able to obtain future financing on favorable terms, or at all. If we fail to obtain sufficient funding when needed, we may be forced to delay, scale back or eliminate all or a portion of our development programs or clinical trials, seek to license to other companies our product candidates or technologies that we would prefer to develop and commercialize ourselves, or seek to sell some or all of our assets or merge with or be acquired by another company.
We recorded net income in the quarter ended March 31, 2014 of $4.7 million as compared to a net loss in the quarter ended March 31, 2013 of $6.9 million, or an increase of $11.6 million, due principally to the recording of a gain of $14.7 million on warrant derivative liabilities in the current period, as compared to a loss of $2.1 million in the 2013 comparative period, for a difference of $16.8 million. In the current period, there was also an increase of approximately $3.8 million in our research and development expenditures as compared to the quarter ended March 31, 2013, due to the increase in expenditures associated with our clinical programs for aldoxorubicin. The general and administrative expenses in the current period also increased by approximately $1.3 million as compared to the quarter ended March 31, 2013, due to compensation increases of approximately $0.4 million, additional legal fees of around $0.6 million, and approximately $0.3 million of non-cash expenses.
We purchased $23.5 million of short-term investments in the three-month period ended March 31, 2014, as compared to the sale of short-term investments of $3.0 million in the comparative 2013 period. We utilized approximately $7,000 for capital expenditures in the three-month period ended March 31, 2014 as compared to approximately $2,000 in the comparable 2013 period. We do not expect any significant capital spending during the next 12 months.
We raised net proceeds of $80.5 million for a public offering in the three-month period of March 31, 2014. We also received $0.4 million from the exercise of warrants in the three-month period ended March 31, 2014, as compared to $0 in the comparative 2013 period.
We continue to evaluate potential future sources of capital, as we do not currently have commitments from any third parties to provide us with additional capital. The results of our technology licensing efforts and the actual proceeds of any fund-raising activities will determine our ongoing ability to operate as a going concern. Our ability to obtain future financings through joint ventures, product licensing arrangements, royalty sales, equity financings, grants or otherwise is subject to market conditions and our ability to identify parties that are willing and able to enter into such arrangements on terms that are satisfactory to us. Depending upon the outcome of our fundraising efforts, the accompanying financial information may not necessarily be indicative of our future financial condition.
As a development company that is primarily engaged in research and development activities, we expect to incur significant losses and negative cash flow from operating activities for the foreseeable future. There can be no assurance that we will be able to generate revenues from our product candidates and become profitable. Even if we become profitable, we may not be able to sustain that profitability.
Results of Operations
We recorded net income in the quarter ended March 31, 2014 of $4.7 million as compared to a net loss in the quarter ended March 31, 2013 of $6.9 million, or an increase of $11.6 million, due principally to the recording of a gain of $14.7 million on warrant derivative liabilities in the current period, as compared to a loss of $2.1 million in the 2013 comparative period, for a difference of $16.8 million.
We recognized no licensing revenue in the three-month periods ended March 31, 2014 and 2013. All future licensing fees under our current licensing agreements are dependent upon successful development milestones being achieved by the licensor. During the remainder of 2014, we do not anticipate receiving any significant licensing fees.
Research and Development
| |
|
Three-Month Period Ended
March 31,
|
|
| |
|
2014
|
|
|
2013
|
|
| |
|
(In thousands)
|
|
|
Research and development expenses
|
|
$ |
5,733 |
|
|
$ |
3,084 |
|
|
Non-cash research and development expenses
|
|
|
1,071 |
|
|
|
50 |
|
|
Employee stock option expense
|
|
|
175 |
|
|
|
46 |
|
|
Depreciation and amortization
|
|
|
9 |
|
|
|
9 |
|
| |
|
$ |
6,988 |
|
|
$ |
3,189 |
|
| |
|
|
|
|
|
|
|
|
Research expenses are expenses incurred by us in the discovery of new information that will assist us in the creation and the development of new drugs or treatments. Development expenses are expenses incurred by us in our efforts to commercialize the findings generated through our research efforts. Our research and development expenses, excluding stock option expense, and depreciation and amortization, were $5.7 million for the three-month period ended March 31, 2014 and $3.1 million for the same period ending March 31, 2013.
Research and development expenses incurred during the three-month period ended March 31, 2014 relate to our various development programs. In the three-month period ended March 31, 2014, the development expenses of our program for aldoxorubicin were $4.9 million. The remainder of our research and development expenses primarily related to research and development support costs. We recorded approximately $1.1 million of non-cash stock option and warrant expense in the three-month period ended March 31, 2014 as compared to $0.1 million in the comparative 2013 period. We recorded approximately $0.2 million of employee stock option expense in the three-month period ended March 31, 2014, as compared to $46,000 for the same period in 2013.
General and Administrative Expenses
| |
|
Three-Month Period Ended
March 31,
|
|
| |
|
2014
|
|
|
2013
|
|
| |
|
(In thousands)
|
|
|
General and administrative expenses
|
|
$ |
2,604 |
|
|
$ |
1,584 |
|
|
Non-cash general and administrative expenses
|
|
|
192 |
|
|
|
27 |
|
|
Employee stock option expense
|
|
|
312 |
|
|
|
185 |
|
|
Depreciation and amortization
|
|
|
23 |
|
|
|
21 |
|
| |
|
$ |
3,131 |
|
|
$ |
1,817 |
|
General and administrative expenses include all administrative salaries and general corporate expenses, including legal expenses associated with the prosecution of our intellectual property. Our general and administrative expenses, excluding stock option expense, non-cash expenses and depreciation and amortization, were $2.6 million for the three-month period ended March 31, 2014 and $1.6 million for the same period in 2013.
Employee stock option expense relates to options granted to retain and compensate directors, officers and other employees. We recorded approximately $0.3 million of employee stock option expense in the three-month period ended March 31, 2014, as compared to $0.2 million for the same period in 2013. We recorded approximately $0.2 million of non-employee stock option expense in the three-month period ended March 31, 2014, and $27,000 for the same period in 2013.
Depreciation and Amortization
Depreciation expense reflects the depreciation of our equipment and furnishings.
Interest Income
Interest income was approximately $71,000 for the three-month period ended March 31, 2014, as compared to $40,000 for the same period in 2013.
Item 3. — Quantitative and Qualitative Disclosures About Market Risk
Our exposure to market risk is limited primarily to interest income sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because a significant portion of our investments are in short-term debt securities issued by the U.S. government and institutional money market funds. The primary objective of our investment activities is to preserve principal. Due to the nature of our short-term investments, we believe that we are not subject to any material market risk exposure. We do not have any speculative or hedging derivative financial instruments or foreign currency instruments. If interest rates had varied by 10% in the three-month period ended March 31, 2014, it would not have had a material effect on our results of operations or cash flows for that period.
Item 4. — Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Securities Exchange Act Rule 13a-15(e)) as of the end of the quarterly period covered by this Quarterly Report. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC.
Changes in Controls over Financial Reporting
There was no change in our internal control over financial reporting that occurred during the quarter ended March 31, 2014 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. We continually seek to assure that all of our controls and procedures are adequate and effective. Any failure to implement and maintain improvements in the controls over our financial reporting could cause us to fail to meet our reporting obligations under the SEC’s rules and regulations. Any failure to improve our internal controls to address the weaknesses we have identified could also cause investors to lose confidence in our reported financial information, which could have a negative impact on the trading price of our common stock.
PART II — OTHER INFORMATION
Item 1A. — Risk Factors
We are, and in the future may be, subject to legal or administrative actions that could adversely affect our results of operations and our business.
Claims have been threatened and have been brought against the Company and its officers and/or directors for alleged violations of the securities laws. Adverse outcomes with respect to some or all of these claims may result in significant monetary damages or injunctive relief that could adversely affect the Company’s ability to conduct its business. Defending a lawsuit can be expensive and can divert the attention of key employees from operating the Company’s business. Litigation and other claims are subject to inherent uncertainties and management’s view of these matters may change in the future. A material adverse impact on the Company’s financial statements also could occur for the period in which the effect of an unfavorable final outcome becomes probable and reasonably estimable.
Item 2. — Unregistered Sales of Equity Securities and Use of Proceeds
During the quarterly period covered by this Report, we issued 200,000 shares of our common stock, and options to purchase 25,000 shares of our common stock at an exercise price of $5.60, in unregistered sales of our equity securities, each to KTB Tumorforschungs GmbH, the licensor of aldoxorobucin, in connection with the establishment of our Freiburg, Germany research and development laboratory. We also issued 11,730 shares of our common stock upon the cashless exercise of an outstanding common stock purchase warrant with an exercise price of $2.50 per share. The shares and warrants were issued by us in private placements exempt from registration under the Securities Act of 1933 pursuant to Section 4(2) of the Securities Act of 1933 and Regulation D under the Act. The issuance of the foregoing shares of common stock upon exercise of the warrants also was exempt from registration under Section 4(2) and Regulation D.
Item 6. — Exhibits
The exhibits listed in the accompanying Index to Exhibits are filed as part of this Quarterly Report and incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| |
CytRx Corporation |
|
| |
|
|
|
|
Date: May 1, 2014
|
By:
|
/s/ JOHN Y. CALOZ |
|
| |
|
John Y. Caloz |
|
| |
|
Chief Financial Officer |
|
| |
|
|
|
INDEX TO EXHIBITS
|
Exhibit
Number
|
|
Description
|
|
10.1
|
|
Agreement dated March 14, 2014 to amend a License Agreement dated August 17, 2006 as amended by Letter Agreement dated January 5, 2010 by and between CytRx Corporation and KTB Tumorgesellschaft GmbH (1)
|
|
31.1
|
|
Certification of Chief Executive Officer Pursuant to 17 CFR 240.13a-14(a)
|
|
31.2
|
|
Certification of Chief Financial Officer Pursuant to 17 CFR 240.13a-14(a)
|
|
32.1
|
|
Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
32.2
|
|
Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
101.INS
|
|
XBRL Instance Document
|
|
101.SCH
|
|
XBRL Schema Document
|
|
101.CAL
|
|
XBRL Calculation Linkbase Document
|
|
101.DEF
|
|
XBRL Definition Linkbase Document
|
|
101.LAB
|
|
XBRL Label Linkbase Document
|
|
101.PRE
|
|
XBRL Presentation Linkbase Document
|
______________________________
(1) Incorporated by reference to the Registrant’s 8-K filed on March 17, 2014 (File No. 000-15327)